Lumos Diagnostics (ASX:LDX) Secures Largest FebriDx Purchase Order with iMedical
Major Purchase Order
Lumos Diagnostics has received a purchase order worth US$126,000 from iMedical, Inc. for its FebriDx test. This marks the largest single purchase order since the product’s launch and indicates a rise in US customer adoption and continued market acceptance.
Product Overview
FebriDx is a rapid point-of-care respiratory test that delivers results in approximately 10 minutes from a fingerstick blood sample. The US Food and Drug Administration cleared FebriDx in July 2023 for diagnosing bacterial acute respiratory infections and differentiating them from non-bacterial causes.
Executive Comments
“I’m pleased to see FebriDx gaining traction and acceptance in the market,” said Doug Ward, CEO and Managing Director of Lumos Diagnostics. “It’s a testament to the product’s clinical value and growing demand. Lumos looks forward to working more closely with iMedical to expand FebriDx’s market acceptance and adoption.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
